PMID- 19459763
OWN - NLM
STAT- MEDLINE
DCOM- 20090917
LR  - 20181201
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 11
IP  - 6
DP  - 2009 Jun
TI  - Improved glycemic control and reduction of cardiometabolic risk factors in 
      subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a 
      clinical practice setting.
PG  - 353-9
LID - 10.1089/dia.2008.0090 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) with the presence of metabolic 
      syndrome (MetS) carries increased risk for cardiovascular disease. Adjunctive 
      exenatide treatment in patients with T2DM is associated with improvements in 
      glycemic control coupled with progressive weight reduction. We evaluated 
      exenatide use on glycosylated hemoglobin A1c (HbA(1c)) and cardiometabolic risk 
      factors in patients with T2DM and MetS in a single clinical practice setting. 
      METHODS: A retrospective analysis of clinical data extracted from the records of 
      176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide 
      along with existing therapeutic regimes from 2005 to 2007 was performed. HbA(1c), 
      lipid profiles, blood pressure, and anthropometric measures were evaluated at 
      baseline and after 16 (+/-4) weeks of exenatide therapy. RESULTS: Mean HbA(1c) 
      was significantly reduced from baseline in 16 weeks (P < 0.001), with 68% of 
      patients achieving HbA(1c) <7%. Total, high-density lipoprotein-, and low-density 
      lipoprotein-cholesterol levels decreased significantly. This decline was not 
      attributable to changes in lipid-lowering agents. Significant reductions were 
      also noted in body mass index, mean body weight, and abdominal girth (AG) with 
      the addition of exenatide. Additional analyses showed 76% of subjects lost 
      weight. Lessening of AG was much more pronounced in female compared with male 
      subjects with diabetes (P < 0.032). No consistent changes in blood pressure were 
      observed. CONCLUSIONS: We found that addition of exenatide to an existing 
      treatment regimen in patients with T2DM and MetS resulted in significant 
      reductions in HbA(1c) along with decline in lipids, AG, and body weight. This 
      indicates improvement in these patients' metabolic profiles.
FAU - Bhushan, Rajat
AU  - Bhushan R
AD  - Metabolic Center of Louisiana Research Foundation, Baton Rouge, Louisiana 70808, 
      USA. rbhushan@mc-la.com
FAU - Elkind-Hirsch, Karen E
AU  - Elkind-Hirsch KE
FAU - Bhushan, Madhu
AU  - Bhushan M
FAU - Butler, William J
AU  - Butler WJ
FAU - Duncan, Kelly
AU  - Duncan K
FAU - Marrioneaux, Ory
AU  - Marrioneaux O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Diuretics)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Peptides)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Venoms)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Glucose/drug effects/*metabolism
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Diabetic Angiopathies/*prevention & control
MH  - Diuretics/therapeutic use
MH  - Exenatide
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Metabolic Syndrome/blood/*drug therapy
MH  - Peptides/*therapeutic use
MH  - Retrospective Studies
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Venoms/*therapeutic use
EDAT- 2009/05/23 09:00
MHDA- 2009/09/18 06:00
CRDT- 2009/05/23 09:00
PHST- 2009/05/23 09:00 [entrez]
PHST- 2009/05/23 09:00 [pubmed]
PHST- 2009/09/18 06:00 [medline]
AID - 10.1089/dia.2008.0090 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2009 Jun;11(6):353-9. doi: 10.1089/dia.2008.0090.